Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is 5.47% higher on its value in year-to-date trading and has touched a low of $89.04 and a high of $148.37 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The NBIX stock was last observed hovering at around $140.09 in the last trading session, with the day’s loss setting it -1.12%.
Currently trading at $138.97, the stock is 1.68% and 2.02% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.88 million and changing -0.80% at the moment leaves the stock 15.06% off its SMA200. NBIX registered 34.19% gain for a year compared to 6-month gain of 28.78%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -0.91% loss in the last 1 month and extending the period to 3 months gives it a -0.81%, and is 4.31% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.19% over the week and 2.90% over the month.
Neurocrine Biosciences, Inc. (NBIX) has around 1400 employees, a market worth around $13.83B and $1.89B in sales. Current P/E ratio is 57.19 and Fwd P/E is 19.87. Profit margin for the company is 13.23%. Distance from 52-week low is 56.08% and -6.34% from its 52-week high. The company has generated returns on investments over the last 12 months (10.03%).
The EPS is expected to grow by 105.20% this year
The shares outstanding are 98.70M, and float is at 96.92M with Short Float at 2.50%.
Neurocrine Biosciences, Inc. (NBIX) Insider Activity
The most recent transaction is an insider sale by BENEVICH ERIC, the company’s Chief Commercial Officer. SEC filings show that BENEVICH ERIC sold 19,818 shares of the company’s common stock on Apr 15 ’24 at a price of $133.36 per share for a total of $2.64 million. Following the sale, the insider now owns 40778.0 shares.
Neurocrine Biosciences, Inc. disclosed in a document filed with the SEC on Apr 01 ’24 that Delaet Ingrid (Chief Regulatory Officer) sold a total of 272 shares of the company’s common stock. The trade occurred on Apr 01 ’24 and was made at $137.30 per share for $37346.0. Following the transaction, the insider now directly holds 7507.0 shares of the NBIX stock.
Still, SEC filings show that on Mar 21 ’24, Delaet Ingrid (Chief Regulatory Officer) disposed off 5,000 shares at an average price of $145.06 for $0.73 million. The insider now directly holds 7,507 shares of Neurocrine Biosciences, Inc. (NBIX).
